{'fraction_non_alphanumeric': 0.027554535017221583, 'fraction_numerical': 0.0, 'mean_word_length': 5.75968992248062, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Mechanisms of neuro‐ and cardioprotection of MAS agonists in the TAC model

Alzheimer’s (AD) is a debilitating disease characterized by a loss of memory and executive function. A growing number of studies have shown a direct correlation between hypertension and increased risk of AD‐like symptoms, including cognitive deficits, increased Aβ production and neuronal death. Furthermore, Renin‐Angiotensin System (RAS) targeted anti‐hypertensives reduce risk. This has prompted studies demonstrating that the protective arm of RAS, via activation of the MAS receptor, is reduced in AD patients, suggesting MAS agonists may protect against ROS production and exotoxicity while also increasing cognition and being cardioprotective. We hypothesize that MAS agonists can ameliorate AD‐like pathology in mice using a model of heart failure – transverse aortic constriction (TAC).